Molecular profiling in breast cancer

Breast Cancer and Molecular Medicine

Volumn , Issue , 2006, Pages 977-1006

  Perez, Edith A ^a   Enui, Alexandru E ^b  

^a MAYO CLINIC   (United States)

^b Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78751647152     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-28266-2_45     Document Type: Chapter

References (87)

1. Ayers M et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and flurouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284-93
2. Baselga J (2001) Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials. Oncology 61(Suppl 2):14-21
3. Baselga J et al (2004) Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 31(5 Suppl 10):51-7
4. Bast RC et al (2001) 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-78
5. Brown MP et al (2000) Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci U S A 97:262-7
6. Cardoso F et al (2004) Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-A gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol 24(1):201-9
7. Chang JC et al (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-9
8. Cobleigh MA et al (2003) Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: High throughput RTPCR assay of paraffin-embedded tumor tissues [abstract 3415]. Proc Am Soc Clin Oncol 22:850
9. Coon JS et al (2002) Amplification and overexpression of topoismerase II predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8:1061-7
10. Cronin M et al (2004) Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 164:35-42
11. Di Leo A et al (2001) HER2 and topoisomerase II as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 12:1081-9
12. Di Leo A et al (2002) HER2 amplification and topoisomerase II gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107-16
13. Dowsett M et al (2003) Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centers. J Pathol 199:418-23
14. Durbecq V et al (2004) Topoisomerase II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-Agent doxorubicin or single-Agent docetaxel. Mol Cancer Ther 3(10):1207-14
15. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-42
16. Early Breast Cancer Trialists' Collaborative Group. (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An over view of the randomized trials. Lancet 365:1687-1717
17. Eden P et al (2004) Good Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40:1837-41
18. Eisen MB et al (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95:14863-8
19. Esteban J et al (2003) Tumor gene expression and prognosis in breast cancer: Multi gene RT-PCR assay of paraffin-embedded tissue [abstract 3416]. Proc Am Soc Clin Oncol 22:850
20. Esteva FJ et al (2003) Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients-MD Anderson Clinical Validation Study [abstract 17]. 26th Annual San Antonio Breast Cancer Symposium
21. Fisher B et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-85
22. Frasor J et al (2004) Selective estrogen receptor modulators: Discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522-33
23. Galea MH et al (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22:07-19
24. Gancberg D et al (2002) Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13:1036-43
25. Glanzer JG et al (2004) Expression profiling of small cellular samples in cancer: Less is more. Br J Cancer 90:1111-4
26. Goldhirsch A et al (2003) Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-65
27. Gruvberger S et al (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61:5979-84
28. Gusterson BA et al (1992) Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-56
29. Hanahan D et al (2000) Hallmarks of cancer. Cell 100:57-70
30. Hanna W et al (2002) Review of the literature on HER2/neu testing and the role of HER2/neu as a prognostic and predictive factor in breast cancer-update December 2000 to July 2001. Curr Oncol 9:S2-S17
31. Harbeck N et al (2002) Clinical relevance of invasion factors urokinase-Type plasminogen activator and plasminogen activator inhibitor type I for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 20:1000-7
32. Hayes DF et al (1996) Tumor Marker Utility Grading System: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88;20:1456-66
33. Hayes DF et al (1998) Assessing the clinical impact of prognostic factors: When is statistically significant clinically useful?. Br Cancer Res Treat 52:305-19
34. Hayes DF (2000) Arbiter. Eur J Cancer 36:293-306
35. Hayes DF (2003) Markers of increased risk for failure of adjuvant therapies. Breast 12:543-9
36. Hedenfalk I et al (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 344:539-48
37. Hynes NE et al (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-84
38. Isola JJ et al (2000) Amplification of topoisomerase II is a strong predictor of response to epirubicin-based chemotherapy in HER2/neu positive breast cancer [abstract 21]. Breast Cancer Res Treat 64:31
39. Jarvinen TA et al (1999) Characterization of topoisomerase II gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-50
40. Jarvinen TA et al (2000) Amplification and deletion of topoisomerase II associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-47
41. Keyomarsi K et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566-75
42. King CR et al (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-6
43. Kuerer HM et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-9
44. Look MP et al (2002) Pooled analysis of prognostic impact of urokinase-Type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94:116-28
45. Loprinzi CL et al (2001) Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 19:972-9
46. Ma XJ et al (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci 100(10):5974-9
47. Manders P et al (2004) Complex of urokinase-Type plasminogen activator with its type I inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Cancer 101:486-94
48. Miller DV et al (2004) Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. Mod Pathol 1-9
49. Mills JC et al (2001) DNA microarrays and beyond: Completing the journey from tissue to cell. Nat Cell Biol 3:E175-8
50. Nacht M et al (1999) Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 59:5464-70
51. NIHCDC (2001) National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, National Institutes of Health Consensus Development Panel
52. Paik S et al (2004) Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients-NSABP studies B-20 and B-14 [abstract 24]. 27th Annual San Antonio Breast Cancer Symposium
53. Paik S et al (2004) A multigene assay to predict recurrence of tamoxifen-Treated, node negative breast cancer. N Engl J Med 351:2817-26
54. Paik S et al (2004) Risk classification of breast cancer patients by the recurrence score assay: Comparison to guidelines based on patient age, tumor size, and tumor grade [abstract 104]. 27th Annual San Antonio Breast Cancer Symposium
55. Paik S et al (2002) Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-4
56. Perez EA et al (2004) Improving patient care through molecular diagnostics. Semin Oncol 31:14-20
57. Perez EA et al (2004) HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial [abstract 567]. Proc Am Soc Clin Oncol 23:18
58. Perez EA et al (2002) HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77:148-54
59. Perez EA et al (2005) Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial [abstract 556]. Pro Am Soc Clin Oncol 23:17
60. Perou CM et al (2000) Molecular portraits of human breast tumors. Nature 406:747-52
61. Piccart MJ et al (2000) HER2, a 'predictive factor' ready to use in the daily management of breast cancer patients?. Eur J Cancer 36:1755-61
62. Piccart MJ et al (2004) Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: Are the results still outperforming the clinical-pathological criteria?. [abstract 38] 27th Annual San Antonio Breast Cancer Symposium
63. Piccart MJ et al (2005) ABREAST: A new global registry of adjuvant strategies in patients with early breast cancer [abstract 576]. Pro Am Soc Clin Oncol 23:22
64. Porter DA et al (2001) A SAGE (Serial Analysis of Gene Expression) view of breast tumor progression. Cancer Res 61:5697-5702
65. Pusztai L et al (2003) Clinical application of cDNA microarrays in oncology. Oncologist 8:252-8
66. Pusztai L et al (2004) Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips. J Clin Oncol 22(14S):503
67. Pusztai L et al (2003) Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 9(7):2406-15
68. Ravdin PM et al (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-91
69. Roche PC et al (2002) Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94:855-7
70. Romond E et al (2005) Joint analysis of NSABP-B-31 and NCCTG-N983. Proc Am Soc Clin Oncol, in press
71. Schulze A et al (2001) Navigating gene expression using microarrays-A technology review. Nat Cell Biol 3:E190-5
72. Slamon DJ et al (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-82
73. Slamon DJ et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-12
74. Slamon DJ et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-92
75. Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-74
76. Sorlie T et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418
77. Sotiriou C et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci U S A 100(18):10393-8
78. Sotiriou C et al (2002) Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4(3):R3
79. Symmans WF et al (2003) Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97:2960-71
80. Tanner M et al (2001) Amplification of HER2/neu and topoisomerase II in primary and metastatic breast cancer. Cancer Res 61:5345-8
81. Tuma RS (2004) A big trial for a new technology: TransBIG Project takes microarrays into clinical trials. J Natl Cancer Inst 96(9):648-9
82. Van De Vijver MJ et al (2004) Correlation of chromogenic in situ hybridization (CISH) with FISH and IHC for assessment of HER2 gene amplification: An international validation ring study [abstract 157]. Eur J Cancer 2(Suppl 3):99
83. Van De Vijver MJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
84. van't Veer LJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-6
85. Vogel CL et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-26
86. West M et al (2001) Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98:11462-7
87. Yaziji H et al (2004) HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291(16):1972-7